{"nctId":"NCT00072462","briefTitle":"Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ","startDateStruct":{"date":"2003-09"},"conditions":["Breast Cancer"],"count":2980,"armGroups":[{"label":"Anastrozole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anastrozole"]},{"label":"Tamoxifen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tamoxifen citrate"]}],"interventions":[{"name":"tamoxifen citrate","otherNames":["Nolvadex"]},{"name":"Anastrozole","otherNames":["Arimidex"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of ductal carcinoma in situ within the past 6 months\n\n  * Locally excised with tumor-free margins at least 1 mm\n* Hormone receptor status:\n\n  * Estrogen or progesterone receptor positive\n\n    * Equal to or greater than 5% positive cells\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 40 to 70\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined as meeting at least 1 of the following criteria:\n\n  * Over age 60\n  * Prior bilateral oophorectomy\n  * Age 60 or under with a uterus AND amenorrhea for at least the past 12 months\n  * Age 60 or under without a uterus AND follicle-stimulating hormone greater than 20 IU/L\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* At least 10 years\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nCardiovascular\n\n* No prior deep vein thrombosis\n* No prior transient ischemic attack\n* No prior cerebrovascular accident\n\nPulmonary\n\n* No prior pulmonary embolism\n\nOther\n\n* No unexplained postmenopausal bleeding\n* No other cancer within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix\n* No other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results\n* No evidence of osteoporosis\n* Fragility fractures within the spine allowed if T-score level is greater than -4 and consist of no more than 2 fractures\n* Psychologically and physically suitable for 5 years of study therapy\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* No prior or concurrent tamoxifen use lasting more than 6 months unless treatment was completed more than 5 years ago. Women in IBIS-I can join if off trial therapy for at least 5 years.\n* No prior or concurrent raloxifene use lasting more than 6 months unless treatment was completed more than 5 years ago.\n* No other prior or concurrent selective estrogen-receptor modulator use lasting more than 6 months unless treatment was completed more than 5 years ago\n* No concurrent systemic estrogen-based hormone replacement therapy, including vaginal estrogen preparations\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* See Disease Characteristics\n* No prior mastectomy\n* No planned prophylactic mastectomy\n\nOther\n\n* At least 3 months since prior unapproved or experimental agents\n* No concurrent anticoagulants","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ER- Breast Cancer Recurrence","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Breast Cancer Deaths","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Non-breast Cancer Deaths","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":333,"n":1449},"commonTop":["Hot flush","Arthralgia","Night sweats","Vulvovaginal dryness","Hot flush"]}}}